Details for Patent: 8,188,085
✉ Email this page to a colleague
Which drugs does patent 8,188,085 protect, and when does it expire?
Patent 8,188,085 protects BREXAFEMME and is included in one NDA.
This patent has nine patent family members in seven countries.
Summary for Patent: 8,188,085
| Title: | Antifungal agents |
| Abstract: | Novel derivatives of enfumafungin are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antifungal agents and/or inhibitors of (1,3)-.beta.-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions. |
| Inventor(s): | Greenlee; Mark L. (Plainfield, NJ), Wilkening; Robert (Maplewood, NJ), Apgar; James (Edison, NJ), Sperbeck; Donald (East Hanover, NJ), Wildonger; Kenneth J. (Bridgewater, NJ), Meng; Dongfang (Westfield, NJ), Parker, Jr.; Dann L. (Cranford, NJ), Pacofsky; Gregory J. (Raleigh, NC), Heasley; Brian H. (Wake Forest, NC), Mamai; Ahmed (Raleigh, NC), Nelson; Kingsley (Mebane, NC) |
| Assignee: | Merck Sharp & Dohme Corp. (Rahway, NC) Seynexis, Inc. (Research Triangle Park, NC) |
| Application Number: | 12/461,318 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 8,188,085
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scynexis | BREXAFEMME | ibrexafungerp citrate | TABLET;ORAL | 214900-001 | Jun 1, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF ADULT AND POST-MENARCHAL PEDIATRIC FEMALES WITH VULVOVAGINAL CANDIDIASIS (VVC) | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,188,085
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2009282474 | ⤷ Sign Up | |||
| Canada | 2731941 | ⤷ Sign Up | |||
| China | 102176827 | ⤷ Sign Up | |||
| China | 104877001 | ⤷ Sign Up | |||
| European Patent Office | 2326181 | ⤷ Sign Up | |||
| Hong Kong | 1214271 | ⤷ Sign Up | |||
| Japan | 2011530593 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
